Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data

被引:19
|
作者
Buckley, Benjamin J. R. [1 ,2 ,3 ]
Harrison, Stephanie L. [1 ,2 ,3 ]
Gupta, Dhiraj [2 ]
Fazio-Eynullayeva, Elnara [4 ]
Underhill, Paula [4 ]
Lip, Gregory Y. H. [1 ,2 ,3 ,5 ]
机构
[1] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, William Henry Duncan Bldg, Liverpool L7 8TX, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Univ Liverpool, Dept Cardiovasc & Metab Med, Inst Life Course & Med Sci, Liverpool, Merseyside, England
[4] TriNetX LLC, London, England
[5] Aalborg Univ, Dept Clin Med, Aalborg, Denmark
来源
关键词
atrial fibrillation; cardiomyopathy; comorbidity; MACE; preventive cardiology; secondary prevention; CATHETER ABLATION; HYPERTROPHIC CARDIOMYOPATHY; SYSTOLIC DYSFUNCTION; HEART-FAILURE; MORBIDITY; RISK;
D O I
10.1161/JAHA.121.021970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prevalence of AF in major subtypes of cardiomyopathy and investigate the impact on important clinical outcomes. Methods and Results A retrospective cohort study was conducted using electronic medical records from a global federated health research network, with data primarily from the United States. The TriNetX network was searched on January 17, 2021, including records from 2002 to 2020, which included at least 1 year of follow-up data. Patients were included based on a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy and concomitant AF. Patients with cardiomyopathy and AF were propensity-score matched for age, sex, race, and comorbidities with patients who had a cardiomyopathy only. The outcomes were 1-year mortality, hospitalization, incident heart failure, and incident stroke. Of 634 885 patients with cardiomyopathy, there were 14 675 (2.3%) patients with hypertrophic, 90 117 (7.0%) with restrictive, and 37 685 (5.9%) with dilated cardiomyopathy with concomitant AF. AF was associated with significantly higher odds of all-cause mortality (odds ratio [95% CI]) for patients with hypertrophic (1.26 [1.13-1.40]) and dilated (1.36 [1.27-1.46]), but not restrictive (0.98 [0.94-1.02]), cardiomyopathy. Odds of hospitalization, incident heart failure, and incident stroke were significantly higher in all cardiomyopathy subtypes with concomitant AF. Among patients with AF, catheter ablation was associated with significantly lower odds of all-cause mortality at 12 months across all cardiomyopathy subtypes. Conclusions Findings of the present study suggest AF may be highly prevalent in patients with cardiomyopathy and associated with worsened prognosis. Subsequent research is needed to determine the usefulness of screening and multisdisciplinary treatment of AF in this population.
引用
下载
收藏
页数:14
相关论文
共 50 条
  • [1] Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
    Aslan, Onur
    Yildirim, Sinan
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (04) : 948 - 957
  • [2] Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data
    Moret, Carla
    Acosta-Isaac, Rene
    Mojal, Sergi
    Corrochano, Mariana
    Jimenez, Blanca
    Plaza, Melania
    Souto, Juan Carlos
    PLOS ONE, 2023, 18 (02):
  • [3] Clinical characteristics, management and outcomes of patients with acute coronary syndrome and atrial fibrillation: real-world data from two nationwide registries in Italy
    Luca, Fabiana
    Caretta, Giorgio
    Vagnarelli, Fabio
    Marini, Marco
    Iorio, Annamaria
    Di Fusco, Stefania Angela
    Pozzi, Andrea
    Gabrielli, Domenico
    Colivicchi, Furio
    De Luca, Leonardo
    Gulizia, Michele Massimo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2020, 21 (02) : 99 - 105
  • [4] REAL-WORLD DATA ON INEQUITY IN CLINICAL OUTCOMES AMONG ADULT PATIENTS DIAGNOSED WITH HYPERTROPHIC CARDIOMYOPATHY
    Krishnaswami, S.
    Tyagi, M.
    Cao, Z.
    VALUE IN HEALTH, 2024, 27 (06) : S39 - S39
  • [5] Real-world therapeutic management of stroke survivors with atrial fibrillation, predictors, and clinical outcomes
    Liliana Rodriguez-Bernal, Clara
    Bejarano-Quisoboni, Daniel
    Hurtado, Isabel
    Garcia-Sempere, Anibal
    Peiro, Salvador
    Sanfelix-Gimeno, Gabriel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 211 - 211
  • [6] Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes
    Wang, Zhe
    Zhu, Long-Yang
    Yu, Lu-Yao
    Chen, Wen-Qian
    Chen, Yi-Nong
    Li, Qing
    Liu, Ying
    Jiao, Si-Qi
    Zhai, Zhen-Guo
    Zhao, Li
    Sun, Yi-Hong
    THROMBOSIS RESEARCH, 2022, 218 : 189 - 191
  • [7] Assessing Safety of Anticoagulation for Atrial Fibrillation in Patients with Cirrhosis: A Real-World Outcomes Study
    Song, Justin J.
    Jackson, Nicholas J.
    Shang, Helen
    Honda, Henry M.
    Boulier, Kristin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2024, 29
  • [8] Catheter Ablation Improves Mortality and Other Outcomes in Real-World Patients With Atrial Fibrillation
    Yang, Pil-Sung
    Sung, Jung-Hoon
    Jang, Eunsun
    Yu, Hee Tae
    Kim, Tae-Hoon
    Uhm, Jae-Sun
    Kim, Jong-Youn
    Pak, Hui-Nam
    Lee, Moon-Hyoung
    Joung, Boyoung
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (11):
  • [9] Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
    Kitazono, Takanari
    Ikeda, Takanori
    Ogawa, Satoshi
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Miyamoto, Susumu
    Murakawa, Yuji
    Cavaliere, Mary
    Hayashi, Yasuhiro
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    HEART AND VESSELS, 2020, 35 (03) : 399 - 408
  • [10] Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
    Takanari Kitazono
    Takanori Ikeda
    Satoshi Ogawa
    Jyoji Nakagawara
    Kazuo Minematsu
    Susumu Miyamoto
    Yuji Murakawa
    Mary Cavaliere
    Yasuhiro Hayashi
    Yoko Kidani
    Yutaka Okayama
    Toshiyuki Sunaya
    Shoichiro Sato
    Satoshi Yamanaka
    Heart and Vessels, 2020, 35 : 399 - 408